China Network News: "Transformation Medicine" is a new concept emerging in the international medical field in recent years. With the rapid development of biotechnology (such as high-throughput sequencing technology), it is increasingly possible to realize the industrialization of "transformation medicine".But the university is just a research and development base. It needs a lot of external assistance to go to industrialization. Recently, Jiangxi Boya signed a strategic cooperation agreement with Nanchang University, and the school and enterprise jointly promoted the rapid industrialization of Jiangxi “transformation medicine”. Xin Hongbo, vice president of Nanchang University, and Liang Xiaoming, deputy general manager of Jiangxi Boya, signed the agreement on behalf of both parties.

“Nanchang University Translational Medicine Research Institute” is a platform jointly constructed by the Jiangxi Provincial Government and Nanchang University. The plan to invest 100 million yuan in three years to build a platform has the nature of a public R&D platform. Xin Hongbo, vice president of Nanchang University, said that “transformation medicine” has broad prospects in biopharmaceuticals. “Nanchang University Translational Medicine Research Institute” has many plans and practices in biomedical research, including establishing stem cell banks, developing biochemical reagents, and introducing advanced control. Technical returnees, etc., it can fully interact with biopharmaceutical companies in the province.